title: Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors.
abstract: BACKGROUND
  Benign prostatic hyperplasia (BPH) is the most common cause of lower urinary tract symptom (LUTS) development in men [1]. The intensity of the symptoms may vary from mild to severe, significantly affecting the quality of life. Erectile dysfunction (ED) is one of the most challenging issues in modern urology that significantly influences the quality of life in men worldwide. The objective of this literature review was to analyze the current drug therapies of patients with BPH-LUTS, with the special emphasis on PDE5 inhibitors.
  
  
  METHODS
  The authors searched the literature for the period from 2000 until 2015 in MEDLINE and PubMed.
  
  
  RESULTS
  Twenty-three articles were selected based on their reliability. A detailed analysis of the selected papers was performed. Primary attention was given to articles describing the use of PDE5. Works describing the use of different groups of drugs in patients with BPH-LUTS were also selected.
  
  
  CONCLUSIONS
  The current literature analysis suggests that the introduction of PDE5 inhibitors in clinical practice for the treatment of patients with BPH-LUTS will allow for significant expansion of the therapeutic options for the treatment of this disease.
authors.affiliation: Moscow State University of Medicine and Dentistry, Moscow, Russia.
authors.forename: Konstantin
authors.initials: K
authors.lastname: Kolontarev
authors.affiliation: Moscow State University of Medicine and Dentistry, Moscow, Russia.
authors.forename: Alexander
authors.initials: A
authors.lastname: Govorov
authors.affiliation: Moscow State University of Medicine and Dentistry, Moscow, Russia.
authors.forename: George
authors.initials: G
authors.lastname: Kasyan
authors.affiliation: Eli Lilly Vostok S.A.
authors.forename: Diana
authors.initials: D
authors.lastname: Priymak
authors.affiliation: Moscow State University of Medicine and Dentistry, Moscow, Russia.
authors.forename: Dmitry
authors.initials: D
authors.lastname: Pushkar
keywords: PDE5 inhibitors; benign prostatic hyperplasia (BPH); erectile dysfunction (ED); lower urinary tract symptoms (LUTS)